Farmak to switch to single-tier governance model: abolition of supervisory board

Change in corporate governance architecture

The leading player in the Ukrainian pharmaceutical market, Farmak, is preparing for significant organisational changes. Management plans to abandon the two-tier management system in favour of a single-tier model. This entails the complete liquidation of the existing supervisory board and the formation of a board of directors in its place.

Shareholders are to make the final decision on this matter during a remote session of the general meeting scheduled for 30 November.

Company profile and international certifications

Farmak Group holds leading positions in the domestic Ukrainian market in monetary terms. The business group is actively engaged in exports, supplying medicines to over 60 countries worldwide. The company’s production facilities are located in Ukraine and Spain.

Particular attention should be paid to the Spanish subsidiary, Farmak International. This plant has obtained a European Union Good Manufacturing Practice (EU GMP) certificate. The document confirms compliance with manufacturing standards for sterile dosage forms, specifically injectable preparations in vials.

Ownership structure and financial results

The ultimate beneficial owner of Farmak remains Filia Zhebrovska, who controls 80% of the company’s shares.

Financial indicators indicate stable business growth. According to YouControl data, the revenue of the joint-stock company Farmak increased by 23% in 2025 compared to the previous year, 2024, reaching 13.3 billion hryvnia. Net profit also demonstrated positive dynamics, increasing by 24.3% and exceeding 2 billion hryvnia.